{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000123","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.809506+00:00","generated_at":"2026-06-08T15:32:37.904500+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Caribou Biosciences Q3 net loss $10M, cash $396.7M; pipeline advances with CB-010, CB-011, CB-012","bullets":["Net loss of $10.0M for Q3 2023 vs $26.6M in Q3 2022; revenue $23.7M (incl. $21.5M from AbbVie termination).","Cash, equivalents, and marketable securities $396.7M as of Sept 30, 2023; funding expected into Q4 2025.","CB-010 ANTLER trial dose expansion continues; FDA meeting for pivotal trial planned, data H1 2024.","CB-011 CaMMouflage trial at dose level 2; CB-012 IND cleared, enrollment expected by mid-2024.","Completed $134.4M follow-on offering and received $25M Pfizer investment in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000123","json":"https://secwatch.observer/filing/0001619856-23-000123.json","markdown":"https://secwatch.observer/filing/0001619856-23-000123.md","text":"https://secwatch.observer/filing/0001619856-23-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/0001619856-23-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/crbu-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:32:37.904500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f9aab04affc34d27c939bede2eabcaf6aca00f3","claim":"Caribou Biosciences, Inc. reported third quarter of 2023 results: revenue $23.7 million.","evidence_excerpt":"will be sufficient to fund its current operating plan into Q4 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $23.7 million for the three months ended September 30, 2023, compared to $3.3 2 million for the same period 2022. The increase was primarily due to $21.5 million in revenue recognized under","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/0001619856-23-000123-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"$23.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}